Wall Street brokerages predict that Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) will post ($0.10) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Sunesis Pharmaceuticals’ earnings. The highest EPS estimate is ($0.08) and the lowest is ($0.11). Sunesis Pharmaceuticals posted earnings of ($0.20) per share in the same quarter last year, which would suggest a positive year over year growth rate of 50%. The firm is expected to issue its next earnings results on Tuesday, August 6th.

On average, analysts expect that Sunesis Pharmaceuticals will report full-year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.48) to ($0.37). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.29) per share, with EPS estimates ranging from ($0.67) to $0.48. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow Sunesis Pharmaceuticals.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.08.

A number of research firms recently issued reports on SNSS. Zacks Investment Research upgraded Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research note on Wednesday. ValuEngine downgraded Sunesis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. HC Wainwright restated a “hold” rating and set a $0.50 price target on shares of Sunesis Pharmaceuticals in a research note on Tuesday, March 12th. Finally, Oppenheimer set a $6.00 price target on Sunesis Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 8th.

A number of large investors have recently added to or reduced their stakes in the stock. Aisling Capital Management LP acquired a new stake in Sunesis Pharmaceuticals during the 4th quarter worth approximately $1,092,000. Algert Global LLC acquired a new stake in Sunesis Pharmaceuticals during the 1st quarter worth approximately $25,000. BlackRock Inc. lifted its position in Sunesis Pharmaceuticals by 27.2% during the 1st quarter. BlackRock Inc. now owns 219,135 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 46,852 shares during the period. Fosun International Ltd acquired a new stake in Sunesis Pharmaceuticals during the 1st quarter worth approximately $863,000. Finally, Wells Fargo & Company MN lifted its position in Sunesis Pharmaceuticals by 1,486.5% during the 1st quarter. Wells Fargo & Company MN now owns 939,958 shares of the biopharmaceutical company’s stock worth $1,143,000 after acquiring an additional 880,711 shares during the period. Hedge funds and other institutional investors own 22.93% of the company’s stock.

NASDAQ:SNSS traded down $0.05 during mid-day trading on Thursday, reaching $1.18. 229,166 shares of the stock were exchanged, compared to its average volume of 856,433. The company has a market capitalization of $85.58 million, a PE ratio of -1.57 and a beta of 2.69. Sunesis Pharmaceuticals has a 1 year low of $0.20 and a 1 year high of $2.87.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.

Recommended Story: Conference Calls

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.